Patient P-01831

Synthetic patientNBL-101 · Day 115 · 75+ · F · baseline S15Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

75%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S15
Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 49 SC-12 recommended — Supportive Compound SC-12
Day 50 Patient accepted — Started SC-12 in the companion
Day 56 GI symptom burden −23% vs expected — Supportive Compound SC-12
Day 62 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days

Inflammatory activity-10
GI instability-8
Nutritional resilience+7
Toxicity-6
Treatment adherence+3

What helped?

Supportive Compound SC-12Day 49
Result: symptom burden −23%

LIFE OS recommendation

GI Support Protocol GI-04

80%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 35/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 57
Autonomic recovery ↑65
- WearableResting HR 74 bpm
- Wearable1,462 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 52
Mucosal barrier integrity ↓30
- Daily logGI symptom score 50 and rising
- WearableSleep 5.6 h, below personal baseline

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.1 · butyrate capacity 35/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 52 ms
Sleep: 5.7 h
Steps: 1,983
Resting HR: 77 bpm

Daily log: GI score 50, nutritional resilience 43, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01581	59%	S18	GI-04	improved	51
P-01389	51%	S14	SC-12	improved	46
P-01413	49%	S14	GI-04	improved	44
P-01544	49%	S15	GI-04	improved	50
P-01716	49%	S14	GI-04	improved	56
P-01307	48%	S14	GI-04	improved	43
P-01365	48%	S14	SC-12	improved	49
P-01436	48%	S14	GI-04	improved	38
P-01598	48%	S14	GI-04	no change	45
P-01707	48%	S14	GI-04	improved	57
P-01842	48%	S14	NP-02	improved	55
P-01473	47%	S14	GI-04	improved	51